Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1H-Benzimidazol-5-ylmethanol, also known as 5-(Hydroxymethyl)-1H-benzimidazole, is an organic compound with a significant benzimidazole core that is found in various biologically active compounds. It has a molecular weight of approximately 162.174 g/mol and the molecular formula C8H8N2O. This light yellow solid at room temperature is considered to be of low toxicity but can be an irritant to the eyes and skin.

106429-29-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 106429-29-2 Structure
  • Basic information

    1. Product Name: 1H-Benzimidazol-5-ylmethanol
    2. Synonyms: 5-(HYDROXYMETHYL)-1H-BENZIMIDAZOLE 97;1H-BENZIMIDAZOL-5-YLMETHANOL;5-(Hydroxymethyl)-1H-benzimidazole;5-(Hydroxymethyl)-1H-benzimidazole 97%;1H-Benzimidazole-5-methanol(9CI);(1H-benzo[d]imidazol-5-yl)methanol
    3. CAS NO:106429-29-2
    4. Molecular Formula: C8H8N2O
    5. Molecular Weight: 148.16
    6. EINECS: N/A
    7. Product Categories: BENZIMIDAZOLE
    8. Mol File: 106429-29-2.mol
  • Chemical Properties

    1. Melting Point: 128.5-131
    2. Boiling Point: 469.534 °C at 760 mmHg
    3. Flash Point: 237.766 °C
    4. Appearance: /
    5. Density: 1.36 g/cm3
    6. Vapor Pressure: 0mmHg at 25°C
    7. Refractive Index: 1.721
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: 12.48±0.10(Predicted)
    11. CAS DataBase Reference: 1H-Benzimidazol-5-ylmethanol(CAS DataBase Reference)
    12. NIST Chemistry Reference: 1H-Benzimidazol-5-ylmethanol(106429-29-2)
    13. EPA Substance Registry System: 1H-Benzimidazol-5-ylmethanol(106429-29-2)
  • Safety Data

    1. Hazard Codes: Xn,Xi
    2. Statements: 20/21/22-36/37/38-41-37/38
    3. Safety Statements: 22-26-36/37/39-39
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 106429-29-2(Hazardous Substances Data)

106429-29-2 Usage

Uses

Given the provided materials, there are no specific applications listed for 1H-Benzimidazol-5-ylmethanol. However, its use is primarily in the synthesis of novel chemical structures due to its benzimidazole core, which is a common feature in biologically active compounds. If there were specific applications in different industries, they would be listed as follows:
Used in [Application Industry]:
1H-Benzimidazol-5-ylmethanol is used as [application type] for [application reason]
Since the provided materials do not specify any particular industry or application, this section remains general. Its role in the synthesis of other compounds suggests potential uses in pharmaceuticals, agrochemicals, or other industries where novel chemical entities are being developed.

Check Digit Verification of cas no

The CAS Registry Mumber 106429-29-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,4,2 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 106429-29:
(8*1)+(7*0)+(6*6)+(5*4)+(4*2)+(3*9)+(2*2)+(1*9)=112
112 % 10 = 2
So 106429-29-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H8N2O/c11-4-6-1-2-7-8(3-6)10-5-9-7/h1-3,5,11H,4H2,(H,9,10)

106429-29-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-(Hydroxymethyl)-1H-benzimidazole

1.2 Other means of identification

Product number -
Other names 3H-benzimidazol-5-ylmethanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:106429-29-2 SDS

106429-29-2Relevant articles and documents

Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells

álvarez, Raquel,Gajate, Consuelo,Puebla, Pilar,Mollinedo, Faustino,Medarde, Manuel,Peláez, Rafael

, p. 167 - 183 (2018)

Resistance to combretastatin A-4 is mediated by metabolic modification of the phenolic hydroxyl and ether groups of the 3-hydroxy-4-methoxyphenyl (B ring). Replacement of the B ring of combretastatin A-4 by a N-methyl-5-indolyl reduces tubulin polymerization inhibition (TPI) and cytotoxicity against human cancer cell lines but cyano, methoxycarbonyl, formyl, and hydroxyiminomethyl substitutions at the indole 3-position restores potent TPI and cytotoxicity against sensitive human cancer cell lines. These highly potent substituted derivatives displayed low nanomolar cytotoxicity against several human cancer cell lines due to tubulin inhibition, as shown by cell cycle analysis, confocal microscopy, and tubulin polymerization inhibitory activity studies, and promoted cell killing mediated by caspase-3 activation. Binding at the colchicine site was suggested by molecular modeling studies. Substituted combretastatins displayed higher potencies than the isomeric isocombretastatins and the highest potencies were achieved for the hydroxyiminomethyl (21) and cyano (23) groups, with TPI values in the submicromolar range and cytotoxicities in the nanomolar and subnanomolar range. Dose-response and time-course studies showed that drug concentrations as low as 1 nM (23) or 10 nM (21) led to a complete G2/M cell cycle arrest after 15 h treatment followed by a high apoptosis-like cell response after 48–72 h treatment. The P-glycoprotein antagonist verapamil increased 21 and 23 cytotoxicity to IC50 values of 10?10 M, and highly potentiated the cytotoxic activity in 100-fold of the CHO derivative (17), in A-549 human non-small cell lung cancer cells. The cyano substituted indolecombretastatin 23 is by itself highly potent against rather resistant HT-29 and A-549 cell lines. A 3,4,5-trimethoxyphenyl ring always afforded more potent derivatives than a 2,3,4-trimethoxyphenyl ring.

ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND

-

Paragraph 0157-0158, (2021/10/22)

The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.

Multi-target inhibitor acting on QC and GSK-3[beta]

-

, (2020/04/02)

The invention discloses a multi-target inhibitor acting on QC and GSK-3[beta], wherein the multi-target inhibitor has the structural general formula shown in the specification; according to active center crystal structures of target QC and GSK-3[beta] zymoprotein, with synthesis of multiple high-activity pharmacophores, the multi-target inhibitor capable of acting on QC and GSK-3[beta] at the sametime is prepared through skeletal transition and recombination design; the multi-target inhibitor is a high-activity molecule with multiple target points, the molecular structure diversity of a leaddrug is remarkably expanded, and research and development of innovative anti-AD drugs and AD diagnostic kits are actively promoted.

Preparation method and application of multi-target inhibitor acting on QC and GSK-3beta

-

, (2020/04/17)

The invention discloses a preparation method and application of a multi-target inhibitor acting on QC and GSK-3 beta. The structural general formula of the multi-target inhibitor prepared by the method is shown in the specification. According to the invention, according to active center crystal structures of target QC and GSK-3 beta zymoprotein, multiple high-activity pharmacophores are integrated, the multi-target inhibitor capable of acting on QC and GSK-3 beta at the same time is prepared through framework transition and recombination design, the multi-target inhibitor is molecules with multiple target points and high activity, the molecular structure diversity of a lead drug is remarkably expanded, and the research and development of innovative anti-AD drugs and AD diagnostic kits areactively promoted, and the preparation method of the multi-target inhibitor provided by the invention is simple and easy to operate.

Substituted Pyran Derivatives

-

Paragraph 0163; 0164, (2014/10/29)

Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter system

PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS

-

Page/Page column 29, (2012/08/08)

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof (I) Wherein Y, Z, R3, U, R4, m and n are as defined in the claims.

OXIME COMPOUNDS AND THE USE THEREOF

-

Page/Page column 364, (2008/06/13)

The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CRsu

A facile synthesis of 5(6)-(chloromethyl)benzimidazoles: Replacement of a sulfonic acid functionality by chlorine

Pete, Bela,Szokol, Balint,Toke, Laszlo

, p. 343 - 347 (2008/09/20)

(Chemical Equation Presented) Valuable new synthetic intermediates, 5(6)-(chloromethyl)benzimidazoles, were prepared by the facile elimination of sulfur dioxide under the influence of thionyl chloride from benzimidazole-5(6)- methanesulfonic acids easily

NOVEL INHIBITORS OF GLUTAMINYL CYCLASE

-

Page/Page column 28-29, (2008/12/04)

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2,

NOVEL INHIBITORS OF GLUTAMINYL CYCLASE

-

Page/Page column 36, (2008/12/04)

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R1 represents and R2, R

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 106429-29-2